Recon: US Negotiations Kick Off for $1T Coronavirus Stimulus; UK Bans Parallel Exports of Key Drugs

• The trillion-dollar coronavirus negotiation kicks off (Politico) (CNN)
• States still waiting on coronavirus tests as Trump tells them to do more (Politico)
• Roche CEO says coronavirus test capacity too limited to screen all (Reuters)
• California issues 'stay home' order; US death toll hits 200 (Reuters) (NYTimes) (LA Times) (NBC)
• Schumer urges Trump to invoke Defense Production Act to rush medical equipment to providers  (Politico) (The Hill)
• With Minimal Evidence, Trump Asks FDA to Study Malaria Drugs for Coronavirus (NYTimes) (STAT) (CNN) (BioCentury)
• A drug maker recently doubled the price of chloroquine — but in response to the coronavirus pandemic, it’s cutting it in half (STAT) (Endpoints) (Financial Times)
• Novartis, Mylan and Teva to supply tens of millions of chloroquine tablets to fight COVID-19 (Fierce)
• Potential coronavirus treatment touted by Trump already in shortage, pharmacists say (Reuters)
• Pfizer’s top-selling vaccine won’t prevent Covid-19, but could get a boost because of it (STAT)
• Navarro slams Big Pharma’s lobbying against possible ‘Buy America’ order (STAT)
• J&J aims for US approval of MS drug ponesimod (PMLive) (Endpoints)
• FDA OKs Gilead’s paediatric hep C drug (PharmaTimes) (FDA)
• Four senators sold stocks before coronavirus threat crashed market (The Hill) (ProPublica)
• FDA to relax hand sanitizer rules amid coronavirus outbreak (Reuters) (Bloomberg Law) (FDA)
• NPR Interview with FDA Commissioner Stephen Hahn (NPR) (Transcript)

• Search for Coronavirus Vaccine Becomes a Global Competition (NYTimes)
• World's governments draft manufacturers for virus treatment arsenal (Reuters)
• UK bans parallel exports of key drugs to protect supplies (Reuters)
• EU opens probe into fake coronavirus-related products (Reuters)
• WHO working to ensure supplies of diagnostics, protective gear – Tedros (Reuters)
• Coronavirus: 100,000 More People Worldwide Got Infected In Less Than 2 Weeks (NPR)
• UK government scientists publish evidence on COVID-19 evolution (Reuters)
• Israel approves generic HIV drug to treat COVID-19 despite doubts (Reuters)
• Coronavirus Death Rate in Wuhan Is Lower than Previously Thought, Study Finds (NYTimes) (WSJ)
• China's new imported coronavirus cases at record; no domestic transfers for second day (Reuters)
• WHO: Africa seeing 'extremely rapid evolution' of coronavirus outbreak (The Hill)
• Filing Error Slices Nearly Two Years Off Roche’s UK Lucentis Protection (Pink Sheet-$)
• Health Canada okays GSK unit's monthly HIV injection (Reuters) (Fierce)

• At-home tests for coronavirus are here. Should you take them? (STAT)
• Why the Coronavirus Has Been So Successful (The Atlantic)
• CDC, Emory University set up sites to check coronavirus symptoms online (Reuters)
• Study: Nearly half of COVID-19 patients experience digestive issues (The Hill)
• Coronavirus Tests Are Now Free, but Treatment Could Still Cost You (NYTimes)
• CVS announces first drive-thru coronavirus testing site in Massachusetts (Reuters)
• DARPA’s gambles might have created the best hopes for stopping COVID-19 (BioCentury)
• How to Donate Blood as Coronavirus Threatens the US Supply (NYTimes) (FDA)
• New blood tests for antibodies could show true scale of coronavirus pandemic (Science Mag)
• They Fled Coronavirus in Europe. Border Agents Asked if They’d Visited China or Iran. (NYTimes)
• Governor Expects More Than Half Of Californians To Become Infected With Coronavirus (NPR)
• N.Y. Gov. Cuomo Says '100% Of Workforce Must Stay Home' Due To Coronavirus (NPR)
• Millions Of Older Americans Live In Counties With No ICU Beds As Pandemic Intensifies (KHN)
• Fetal tissue ban blocks study of potential coronavirus therapies (Science Mag)
• Companies are rushing to introduce coronavirus testing kits — and so are scam artists (NBC)
• Faced with a shortage of face masks, some US doctors make their own (Reuters)
• Mask Shortage Straps Pharmacists Who Need Them To Keep Medicines Pure (KHN)
• Come back to fight coronavirus, UK begs 65,000 former nurses and doctors (Reuters)
• Sharp increase in Moscow pneumonia cases fuels fears over coronavirus statistics (Reuters)
• Russia starts testing coronavirus vaccine prototypes on animals (Reuters)
• The biotech start-ups racing to create quicker coronavirus tests (Financial Times)
• Why lifesaving ventilators will be in short supply for the foreseeable future (Vox)
• UK hopes newly-made ventilators will be ready for coronavirus fight next week (Reuters)
• Ferrari and Fiat look at helping Italy make ventilators in coronavirus crisis (Reuters)
• Merck KGaA donates multiple sclerosis med Rebif to French COVID-19 trial (Fierce)
• NBC News employee dies after testing positive for coronavirus (NBC)
• Spain's coronavirus death toll surpasses 1,000 (Reuters)
• Brazil coronavirus cases top 600, diplomatic spat with China bubbles (Reuters)
• Thailand reports 50 new coronavirus infections for total of 322 (Reuters)
• Greece has registered 464 coronavirus cases, six deaths: health min official (Reuters)
• Cambodia reports 10 new cases of coronavirus, bringing total to 47 (Reuters)
• Dutch coronavirus cases up by 534 to 2,994, deaths up 30 to 106 (Reuters)
• Delayed by sanctions, border checks, first medical aid trickles into North Korea (Reuters)
• Mexico coronavirus tally rises to 164 from 118 a day earlier (Reuters)
• Why India may be about to discover "tens of thousands" more coronavirus cases (CBS)
• Tesla suspends production at U.S. vehicle factory due to coronavirus (Reuters)
• Supply-chain recovery in coronavirus times—plan for now and the future (McKinsey)
• 3M Outlines Actions to Support Healthcare Effort to Combat COVID-19 (3M)
• Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials (Press)
• Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) (FDA)

• The Covid-19 crisis is the right time to adopt decentralized clinical trials (MedCity)
• IPO market sealed shut for the foreseeable future: report (Fierce)
• ‘Organ-on-a-chip’ maker Emulate names new CEO, announces new funding (STAT)
• In hard-hit Seattle, coronavirus pushes biotechs to a new normal (BioPharmaDive)
• TV Drug Advertising Spend Rising, But Few Brands Provide Pricing Info (Pink Sheet-$)
• Direct-to-Consumer Prescription Drug Advertising and Patient-Provider Interactions (JABFM)
• Biogen fires staffer who fled to China after she was infected in the biotech’s coronavirus outbreak (Endpoints)
• A key player behind 2 multibillion-dollar biotech M&A deals is back in the startup business (Endpoints)
• Epizyme hires Kutok as CSO to find new uses for Tazverik (Fierce)
• Charles Bancroft makes quick leap from Bristol Myers exec team to GSK; Medicxi adds two new partners to its team (Endpoints)
• InnoCare IPO oversubscribed 300x as Hong Kong investors turned to biotech amid runoff (Endpoints)
• Three Things to Look for in a Patient Assistance Program (Drug Channels)
• Blood Products Advisory Committee; Postponed (FDA)

• AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis (Press)

• Direct-to-consumer companies wade into coronavirus testing to fill gap (MedtechDive)
• Exact Sciences pulls 2020 sales guidance amid coronavirus uncertainty (MedtechDive)
• Co-Diagnostics, Inc Completes Successful Clinical Evaluation Required for FDA Emergency Use Authorization (Press)

• NIH shifts non-mission-critical laboratory operations to minimal maintenance phase (NIH)
• No, Seriously, Don't Try To 'Trademark' Coronavirus (Law360-$)
• Ruling In HHS Case May Mean More Drug Trial Reporting (Law360-$)
• Mylan, Pfizer Want EpiPen Row Paused For Class Cert. Appeal (Law360-$)
• Japanese Device Co. Must Face FCA Suit Over Medicare Fraud (Law360-$)
• PTAB To Review Allergen Juvederm Patent At Heart Of IP Suit (Law360-$)
• Mallinckrodt Files Certiorari Petition in iNO v. Praxair (Patent Docs)
• The Supreme Court Addresses Purposes and Objectives Preemption in a Surprising New Context (Drug & Device Law)
• Preventing other Shkreli-like debacles may not save the government much money (STAT)
• FDA suspends U.S. vape shop inspections as coronavirus spreads (Reuters)

• EMA Management Board – highlights of March 2020 meeting (EMA)
• COVID-19: research package welcomed, EU needs to be better equipped in future (European Parliament)
• Targeted stakeholders' consultation on Annex 21: Importation of medicinal products, of the Eudralex volume 4 (EC)
• Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 17-18 March 2020 (EMA)
• What Might Whistleblower Protections Look Like For UK Pharma Post-Brexit? (Pink Sheet-$)
• The MDR and the Covid-19 recommendation – a possible template for fixing the MDR and IVDR bottleneck (MedicalDevicesLegal)
• MHRA guidance on Coronavirus (COVID-19) (MHRA)
• New arrangements for MHRA Good Practice (GxP) inspections due to coronavirus (COVID-19) (MHRA)
• MHRA services during the Coronavirus (COVID-19) response (MHRA)
• Advertising investigations: February 2020 (MHRA)
• Advertising investigations: January 2020 (MHRA)

• China’s NMPA Steps Up To The Plate In COVID-19 Fight But Much Is Left To Do (MedtechInsight)

• Department of Pharma proposes Rs 10,000-crore incentive scheme for promoting domestic API units (Economic Times)
• Prices of raw materials of hand sanitizers surge 200% due to huge demand since coronavirus outbreak (Pharmabiz)
• Biocon gets EIR from USFDA for manufacturing facility in Bengaluru (Economic Times)
• 14 firms get license to evaluate COVID-19 tests kits (Economic Times)
• A Mumbai company is working on a potential coronavirus medicine (Economic Times)
• ICMR may cap price of each coronavirus test at Rs 4,500-Rs 5,000 for private labs: Official (Economic Times)

• Pricing Reforms Prompt Canadian Business Rethink (Pink Sheet-$)
• Notice: Expedited Review of Health Product Submissions and Applications to address COVID-19 (Health Canada)

• Supplying COVID-19 tests (TGA)
• Surrogate viruses for use in disinfectant efficacy tests to justify claims against COVID-19 (TGA)

• NIH study provides genetic insights into osteosarcoma in children (HIN)